Embecta Corp. (Nasdaq: EMBC), a global medical supplies company with a 100-year legacy in insulin delivery, announced its participation in four major investor conferences in June 2026, including the Jefferies Global Healthcare Conference, TD Cowen Diabetes Tech Summit, Goldman Sachs Global Healthcare Conference, and Truist Securities MedTech Conference. The company will host one-on-one meetings and a fireside session to engage with investors.

Law firm Kirby McInerney LLP is investigating Embecta Corp. following the company's May 5, 2026 earnings report that missed analyst expectations and included reduced full-year guidance. The announcement cited losses in pen needle products at a major customer and market softness in insulin pens. Embecta's stock price plummeted 58% from $9.25 to $3.90 per share on the news. The investigation seeks to determine if federal securities laws were violated.

Embecta Corp (NASDAQ: EMBC) has completed its acquisition of Owen Mumford Holdings Limited, a UK-based medical device manufacturer. The deal, announced in March 2026, includes an upfront payment of £100 million plus up to £50 million in performance-based payments. The acquisition accelerates embecta's transformation into a broad-based medical supplies company with expanded drug delivery platforms and chronic care device portfolios across obesity, diabetes, autoimmune diseases, and anaphylaxis markets.

Embecta's stock crashed 57.8% following disappointing fiscal Q2 2026 results. The medical-device company reported adjusted EPS of $0.27 on sales of $221.8 million, significantly missing analyst expectations of $0.42 EPS and $235.7 million in sales. Sales declined 14.4% year-over-year with EBITDA margins compressing to 29.1% from 37.5%. The company substantially lowered full-year guidance for both sales and adjusted operating margins, raising concerns about near-term growth prospects.

Embecta Corp (NASDAQ: EMBC) announced a quarterly cash dividend of $0.01 per share, payable on June 15, 2026 to shareholders of record as of May 28, 2026. The company continues its legacy in insulin delivery while expanding into broader medical supplies.

Embecta Corp. (Nasdaq: EMBC) announced it will host a conference call on May 5, 2026, at 8:00 a.m. ET to discuss its fiscal second quarter 2026 financial results and provide an operational update. The global medical supplies company, with a 100-year legacy in insulin delivery, will also hold a question and answer session accessible via live webcast and teleconference.

Embecta agreed to acquire Owen Mumford Holdings Limited for up to $200 million (150 million pounds), including a $134 million upfront payment and up to $67 million in performance-based payments. The acquisition aims to enhance Embecta's drug-delivery capabilities and expand into chronic care markets. The deal is expected to close in Q3 fiscal 2026 and contribute to revenue growth from fiscal 2027 onward, though it will be dilutive to adjusted net income in 2027. Embecta shares rose 4.63% to $8.98 on the announcement.

Embecta Corp has entered into a definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based medical device and drug-delivery technology company, for up to £150 million (£100 million upfront plus up to £50 million in performance-based payments). The acquisition is expected to expand embecta's product portfolio, accelerate growth in chronic care markets, and leverage complementary manufacturing capabilities and global commercial infrastructure.

The article examines three high-yielding healthcare stocks: Perrigo (8.2% yield) is cautioned as a potential value trap despite strong dividend history; Pfizer (6.7% yield) is viewed more favorably with post-COVID catalysts and GLP-1 product launches; Embecta (5.5% yield) shows turnaround potential as it pivots toward the GLP-1 pen needle business.

Embecta Corp. (Nasdaq: EMBC) announced a quarterly cash dividend of $0.15 per share, payable on March 17, 2026 to shareholders of record as of February 27, 2026. The company continues its operations as a global medical supplies provider focused on insulin delivery solutions.

Embecta Corp. (NASDAQ: EMBC), a global medical supplies company with a 100-year legacy in insulin delivery, announced it will host a conference call on February 5, 2026, at 8:00 a.m. ET to discuss its fiscal first quarter 2026 financial results and provide an operational update. The live webcast will be accessible via the company's investor relations website.

Embecta Corp. declared a quarterly cash dividend of $0.15 per share, payable on December 18, 2025. The company also announced board changes, with David J. Albritton resigning and David F. Melcher planning to retire.